Table 2.
Distribution of the next therapeutic steps by case race and ethnicity among 159 respondents
| Black case | Hispanic case | White case | |
|---|---|---|---|
| Case 1 | N = 54 | N = 53 | N = 52 |
| Add low‐dose prednisone | 1 (1.9%) | 3 (5.7%) | 1 (1.9%) |
| Continue current therapy and monitoring for now | 6 (11.1%) | 3 (5.7%) | 5 (9.6%) |
| Increase dose of oral methotrexate | 6 (11.1%) | 7 (13.2%) | 10 (19.2%) |
| Start a biologic therapy | 41 (75.9%) | 37 (69.8%) | 34 (65.4%) |
| Switch methotrexate to leflunomide | 0 (0%) | 3 (5.7%) | 2 (3.8%) |
| Case 2 | N = 57 | N = 52 | N = 50 |
| Continue current therapy and prescribe antidiarrheal medication | 8 (14.0%) | 11 (21.2%) | 10 (20.0%) |
| Continue current therapy and reassess in 3 mo | 6 (10.5%) | 5 (9.6%) | 10 (20.0%) |
| Start combination leflunomide and methotrexate at lower doses and stop sulfasalazine | 5 (8.8%) | 2 (3.8%) | 3 (6.0%) |
| Stop sulfasalazine and start a biologic therapy | 35 (61.4%) | 32 (61.5%) | 26 (52.0%) |
| Switch from leflunomide back to methotrexate at a lower dose and stop sulfasalazine | 3 (5.3%) | 2 (3.8%) | 1 (2.0%) |
| Case 3 | N = 53 | N = 53 | N = 53 |
| Add hydroxychloroquine | 15 (28.3%) | 10 (18.9%) | 12 (22.6%) |
| Add low‐dose prednisone | 1 (1.9%) | 1 (1.9%) | 3 (5.7%) |
| Start a biologic therapy | 35 (66.0%) | 36 (67.9%) | 32 (60.4%) |
| Switch methotrexate to leflunomide | 0 (0%) | 4 (7.5%) | 3 (5.7%) |
| Continue current therapy and monitoring for now | 2 (3.8%) | 2 (3.8%) | 3 (5.7%) |
| Case 4 | N = 54 | N = 53 | N = 52 |
| Add prednisone | 3 (5.6%) | 1 (1.9%) | 1 (1.9%) |
| Start a biologic therapy | 50 (92.6%) | 52 (98.1%) | 50 (96.2%) |
| Increase dose of methotrexate | 0 (0%) | 0 (0%) | 1 (1.9%) |
| Switch methotrexate to leflunomide | 1 (1.9%) | 0 (0%) | 0 (0%) |